Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Retatrutide for Sale > Tirzepatide GLP-1 10mg Reta 15mg 10vials a box
Tirzepatide GLP-1 10mg Reta 15mg 10vials a box buy - large image1
Tirzepatide GLP-1 10mg Reta 15mg 10vials a box buy - image1
Tirzepatide GLP-1 10mg Reta 15mg 10vials a box buy - image2
Tirzepatide GLP-1 10mg Reta 15mg 10vials a box buy - image3

Tirzepatide GLP-1 10mg Reta 15mg 10vials a box

GMP ISO TDS 7504 Inquiries

Unit Price:

$2.5/KG EXW

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99.68%

Port:

world

Brand:

Million

Packaging:

25kg/Cardboard Drum

Sample Available:

Yes

Price valid (until):

2100-12-31

Company Type:
Manufactory
Location:
China
Payment Terms:
L/C,100% TT in advance
Average Lead Time:
3 days
Qualification:
Main Products:

Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2

  • Product Details

  • Seller Information

  • Inquiry History

  • Description
    Tirzepatide
    Semaglutide
    Retatrutide
    Mazdutide
    GHK-cu

    Founded in 2012, Jinan Million Pharmaceutical Co., Ltd (Jinan Milin Pharmaceutical Co., Ltd) is a modern pharmaceutical enterprise guided by innovation. Million pharm has excellent research and development capabilities and complete industrial bases with international quality management system. It is dedicated to the research, development, production and customization of pharmaceuticals and advanced pharmaceutical intermediates.

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates
    • Tirzepatide GLP-1 10mg Reta 15mg 10vials a box Certificates 3 TDS

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2

    Location:

    Room 1-2208, Lianhecaifu Square, No2177, Tianchen Road, Gaoxin District, Jinan City, Shandong Province, China

    Payment Terms:

    L/C,100% TT in advance

    Average lead Time:

    3 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2012

    Company Certificates
    • Jinan Million Pharmaceutical Co., Ltdbusiness license business license

    Founded in 2012, Jinan Million Pharmaceutical Co., Ltd (Jinan Milin Pharmaceutical Co., Ltd) is a modern pharmaceutical enterprise guided by innovation. Million pharm has excellent research and development capabilities and complete industrial bases with international quality management system. It is dedicated to the research, development, production and customization of pharmaceuticals and advanced pharmaceutical intermediates.
     
    Jinan Million Pharmaceutical Co., Ltd has been focusing on the research of Cerebro-cardiovascular drugs, Central nervous system drugs, Anti-cancer drugs, Antibacterial drugs and others for 12 years; the products are: Apixaban, Lurasidone, Bexagliflozin, Votioxitine, Loxo-292/Selpercatinib, Baricitinib and intermediates. Million has worked with reputable customers, like METROCHEM API PVT LTD; BDR LIFESCIENCES PVT.LTD; INCETPAT PHARM; SRINI CHEM; EVA PHARMA; PHARMAFFILIATES ANALYTICS & SYNTHETICS (P) LTD; ....from India, Egypt, Canada...



    Jinan Million Pharmaceutical Co., Ltd has a 1,500㎡ R&D center in the Zhongguancun E Valley (Qihe) Incubator, equipped with complete test equipment, such as high-performance liquid chromatography, nuclear magnetic resonance spectrometer, liquid chromatography mass spectrometer, automatic polarimeter, etc., which can meet the needs of various  laboratory scale tests in different conditions. The pilot workshop is equipped with 50L and 100L glass reactors, high and low temperature equipment, etc., which can support organic chemical reactions at -100°C or 200°C. In addition, Million has a production site in Linyi city with many independent production lines, such as: production line of Apixabn intermediate 20 tons/year, production line of Lurasidon intermediate 10 tons/year, which can meet the commercial production of various products.
     
    The technical team is composed of high-level talents in major of pharmacy, bio-pharmaceutical or chemical synthesis, of which 10% has doctor’s degree and 15% has master’s degree. The team members are young and energetic with innovative spirit and willing to overcome obstacles.
     
    Jinan Million Pharmaceutical Co., Ltd adheres to the business philosophy of "dedication and innovation", insists on pioneering and innovating, constantly improves the quality system, and vigorously trains technical and management talents to build an elite team and serves customers better. Looking forward to cooperate with you for joint development and common progress.

  • Inquiry History
    7504 Inquiries
    Country Product Purchase Quantity Date Posted
    Malaysia

    Retatrutide

    20 MG Oct 28, 2026
    Brazil

    Retatrutide

    10  Oct 29, 2026
    Australia

    Retaturtide

    100 MG Oct 29, 2026
    United States

    Retatrutide 30mg and 50mg

    20 PCS Oct 29, 2026
    Belgium

    Retatrutide

    1 MG Oct 29, 2026
    Romania

    Retatrutide

    10 G Oct 29, 2026
    United States

    Retatrutide

    2 MT Oct 29, 2026
    United States

    Retatrutide

    1 MT Oct 29, 2026
    United Kingdom

    Retatrutide

    1 PCS Oct 28, 2026
    United States

    Retatrutide

    30 MT Oct 28, 2026
    United Kingdom

    Retatrutide

    10 MT Oct 28, 2026
    United States

    retatrutide

    30 MG Oct 28, 2026
    Czech

    Retatrutide

    10 MG Oct 28, 2026
    Austria

    retatrutide

    30 MG Oct 28, 2026
    United States

    Retatrutide

    100 KG Oct 28, 2026
    Malta

    Retatrutide

    10 MT Oct 28, 2026
    United States

    Retatrutide

    600 MG Oct 28, 2026
    United States

    Retatrutide

    500 G Oct 28, 2026
    United States

    Retatrutide

    60 G Oct 28, 2026
    Croatia

    Retatrutide

    10 MG Oct 28, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.